MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
68.62
-2.25
-3.17%
After Hours: 68.70 +0.08 +0.12% 19:53 04/12 EDT
OPEN
70.00
PREV CLOSE
70.87
HIGH
70.81
LOW
68.42
VOLUME
2.73M
TURNOVER
0
52 WEEK HIGH
99.41
52 WEEK LOW
8.28
MARKET CAP
7.56B
P/E (TTM)
-75.3735
1D
5D
1M
3M
1Y
5Y
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
NASDAQ · 4d ago
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
MarketWatch · 4d ago
Novo Nordisk: The Moat Won't Last Forever
Novo Nordisk A/S has more than doubled since late 2022. The GLP-1 market is projected to grow to $100 billion by 2030. Novo Nordisk is the preeminent player in the weight loss space. The company faces stiffening competition from Eli Lilly and Company and new entrants on the horizon.
Seeking Alpha · 5d ago
ClearBridge Small Cap Growth Strategy Q2 2024 Portfolio Manager Commentary
Seeking Alpha · 5d ago
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.
Seeking Alpha · 5d ago
This Small-Cap Biotech Could Gain Over 165%, Says Wall Street
Terns Pharmaceuticals (TERN) is a clinical-stage biopharma company developing drugs for oncology and obesity. Shares of Terns went public in early 2021 and currently trade 81% below all-time highs. Mizuho is bullish on the company's drug pipeline, including an oral treatment for weight loss. Morgan Stanley has projected the global weight-loss drug market could reach $77 billion by 2030.
Barchart · 6d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 6d ago
Weekly Report: what happened at VKTX last week (0401-0405)?
Weekly Report · 6d ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.